KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt Ratio (2019 - 2025)

Royalty Pharma's Debt Ratio history spans 7 years, with the latest figure at 0.46 for Q4 2025.

  • For Q4 2025, Debt Ratio rose 9.2% year-over-year to 0.46; the TTM value through Dec 2025 reached 0.46, up 9.2%, while the annual FY2025 figure was 0.46, 9.2% up from the prior year.
  • Debt Ratio for Q4 2025 was 0.46 at Royalty Pharma, down from 0.46 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.46 in Q3 2025 and bottomed at 0.35 in Q3 2022.
  • The 5-year median for Debt Ratio is 0.42 (2022), against an average of 0.41.
  • The largest annual shift saw Debt Ratio fell 13.43% in 2022 before it rose 13.67% in 2025.
  • A 5-year view of Debt Ratio shows it stood at 0.41 in 2021, then increased by 2.91% to 0.42 in 2022, then decreased by 11.51% to 0.37 in 2023, then rose by 11.54% to 0.42 in 2024, then rose by 9.2% to 0.46 in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Debt Ratio are 0.46 (Q4 2025), 0.46 (Q3 2025), and 0.44 (Q2 2025).